Jasper Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Jasper Therapeutics, Inc. filed a Form 8-K on June 27, 2022, reporting matters from its June 23, 2022 Annual Meeting of Stockholders. The filing concerns corporate governance and auditor ratification; it does not provide operating or financial-period results.
Meeting Participation and Voting Results
A total of 19,415,543 shares, representing approximately 53% of the 36,579,906 shares outstanding as of the April 26, 2022 record date, were represented at the meeting.
| Proposal | Result |
|---|---|
| Election of Kurt von Emster as Class I director | Elected; 17,769,058 votes for, 324,016 withheld, and 1,322,469 broker non-votes |
| Election of Lawrence Klein, Ph.D. as Class I director | Elected; 17,890,093 votes for, 202,981 withheld, and 1,322,469 broker non-votes |
| Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2022 | Ratified; 19,074,569 votes for, 340,973 against, and 1 abstention |
Financial Metrics and Material Changes
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics. It does not report a material change versus a prior comparable period.
Outlook, Risks, and Unusual Items
No management outlook, risk update, contingency, financing transaction, or unusual accounting item is disclosed in the filing. The principal reported developments are the election of two directors and the ratification of the independent auditor.
Investor Verification Items
- Verify the director terms and board composition in subsequent proxy statements or SEC filings.
- Confirm PricewaterhouseCoopers LLP’s appointment and review subsequent auditor-related disclosures.
- Review the company’s periodic reports for financial performance, cash runway, financing needs, and clinical or business updates, none of which are addressed in this Form 8-K.
- Note that approximately 47% of shares outstanding were not represented at the meeting based on the disclosed figures.